섬유이형성증 진행성 골이형성증(FOP) 참가자에 대한 팔로바로텐의 장기적인 안전성과 유효성을 문서화하고 추가 설명하기 위한 연구 (FOPal)
섬유이형성증 골화이형성증(FOP) 환자에 대한 팔로바로텐의 장기 안전성 및 유효성을 추가로 설명하기 위한 국제 관찰 레지스트리 연구
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
연구 개요
상태
상태
정황
정황
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ipsen Clinical Study Enquiries
- 전화번호: see email
- 이메일: clinical.trials@ipsen.com
연구 장소
-
-
California
-
San Francisco, California, 미국, 94103
- 모병
- The Regents of the University of California
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
-
-
-
-
-
Edmonton, 캐나다
- 모병
- Edmonton Clinic Health Academy (ECHA)- University of Alberta
-
Oakville, 캐나다
- 모집하지 않고 적극적으로
- Bone Research and Education Centre
-
Toronto, 캐나다
- 모병
- University Health Network (UHN) - Toronto General
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
설명
Inclusion Criteria :
- Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
- Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
- Currently participating in a palovarotene clinical trial;
- Currently participating in any interventional clinical trial for FOP;
- Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Exposed Cohort
Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) |
|
Unexposed Cohort
Participants untreated with palovarotene |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
기간: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC). |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
기간: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
기간: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
기간: From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
재발 횟수
기간: 포함 전 12개월부터 기준 최대 11년까지.
|
포함 전 12개월부터 기준 최대 11년까지.
|
|
|
참가자 당 영향을받는 위치 수
기간: 기준선에서 매년 11 년까지.
|
기준선에서 매년 11 년까지.
|
|
|
위치 당 영향을받는 위치의 진화 (위치가 몇 배나 영향을 받음)
기간: 기준선에서 매년 11 년까지.
|
기준선에서 매년 11 년까지.
|
|
|
만성 치료를 위해 FOP가 노출되어 팔로바로틴에 노출되어 노출되지 않은 참가자에 대한 평균 복용량/연간
기간: 기준선과 6 개월마다 11 년.
|
기준선과 6 개월마다 11 년.
|
|
|
FLARE-UP 치료를 위해 FOP가 노출되고 팔로바로틴에 노출되지 않은 참가자를위한 Palovarotene의 평균 용량/사이클
기간: 기준선과 6 개월마다 11 년.
|
기준선과 6 개월마다 11 년.
|
|
|
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
기간: From Baseline and every six months up to eleven years.
|
The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in use of assistive devices
기간: From Baseline and every six months up to eleven years.
|
Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
기간: From Baseline and every six months up to eleven years.
|
Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
기간: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
기간: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
기간: From Baseline and every six months up to eleven years.
|
The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
기간: From Baseline and every six months up to eleven years.
|
The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
기간: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:
|
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
기간: From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
기간: From Baseline and every six months up to eleven years.
|
The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit. |
From Baseline and every six months up to eleven years.
|
|
Number of flare-up outcomes
기간: From Baseline and every six months up to eleven years.
|
Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported. |
From Baseline and every six months up to eleven years.
|
|
Flare-up Duration
기간: From Baseline and every six months up to eleven years.
|
Flare-up duration will be assessed by body location and overall, at each visit. |
From Baseline and every six months up to eleven years.
|
|
Movement mobility change
기간: From Baseline and annually up to eleven years.
|
Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement) |
From Baseline and annually up to eleven years.
|
|
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
기간: From Baseline and every six months up to eleven years.
|
The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected. |
From Baseline and every six months up to eleven years.
|
|
Percentage of participants with any fractures overall
기간: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Change from Baseline in annualized number of fractures by body location and overall
기간: From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Incidence of pregnancy
기간: From Baseline and every month up to 30 days after the last palovarotene dose.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified |
From Baseline and every month up to 30 days after the last palovarotene dose.
|
|
Description of pregnancy characteristics and outcomes
기간: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of pregnancy related Adverse Events (AEs)
기간: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
기간: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
기간: From Baseline and every six months up to eleven years.
|
Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in height z-score
기간: From Baseline and every six months up to eleven years.
|
Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Mean difference between chronological age and bone age
기간: From Baseline and every six months up to eleven years.
|
Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Frequency of premature physeal closure (PPC) overall
기간: From baseline up to 30 days after the last palovarotene dose
|
Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From baseline up to 30 days after the last palovarotene dose
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Ipsen Medical, Director, Ipsen
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CLIN-60120-453
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 공유 기간
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 공유 액세스 기준
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .